scholarly journals Triple negative breast cancer - current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment

2009 ◽  
Vol 153 (1) ◽  
pp. 13-17 ◽  
Author(s):  
Katerina Bouchalova ◽  
Magdalena Cizkova ◽  
Karel Cwiertka ◽  
Radek Trojanec ◽  
Marian Hajduch
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Targeted Treatment ◽  
Current Status ◽  
Myc Gene

Expression of Transgelin in Triple Negative and Non Triple Negative Breast Cancer: A Differential Study

2020 ◽  
Vol 106 (1_suppl) ◽  
pp. 20-20
Author(s):  
NS Tolba ◽  
AS Alsedfy ◽  
SW Skandar ◽  
YM El-Kerm
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Molecular Subtypes ◽  
High Rate ◽  
Targeted Treatment ◽  
Her2 Status ◽  
Altered Expression ◽  
Wide Range ◽  
Significant Difference

Introduction: Triple negative breast cancer (TNBC) is defined by the absence of ER expression, PR expression and HER2 amplification. No targeted treatment is available for TNBC and chemotherapy remains the best therapeutic option. However, in the case of recurrence or chemo-resistance, therapeutic options are very limited. TNBC presents a high rate of proliferation and is highly aggressive having low survival rate. As the complexity of this disease is being simplified over time, new targets are also being discovered for the treatment of this disease. Therefore, there is still need for new biomarkers, which would serve for targeted treatment. Transgelin was proposed as a new potential cancer biomarker. Altered expression of Transgelin has been described in a wide range of cancers, often with contradictory results. The aim of the study was to compare Transgelin expression across molecular subtypes of breast cancer, to identify if it can be used as a future molecular targeted protein for TNBC. Material and Methods: Transgelin immunohistochemistry was applied on 60 retrospectively collected paraffin blocks of patients presenting with invasive breast carcinoma (NST) having different molecular subtypes. Blocks were collected between 2015 and 2016 from Pathology department, Medical Research Institute, Egypt. Her2 equivocal cases were excluded from the study. Results: Transgelin expression was positive in 23 cases and negative in 37 cases. There was a statistically significant difference between (Transgelin +) and (Transgelin -) cases being highly expressed in TNBC in comparison to other molecular subtypes. It was also highly expressed in tumors with large size, high grade, positive lymph-vascular invasion status & lymph node metastasis. There was no statistically significant difference between (Transgelin+) and (Transgelin-) as regards age and Her2 status. Conclusions: Transgelin is an aggressive biomarker differentially expressed among the molecular breast cancer subtypes with high expression in TNBC. Transgelin may provide a potential target for future treatment of TNBC.

A versatile theranostic nanodevice based on an orthogonal bioconjugation strategy for efficient targeted treatment and monitoring of triple negative breast cancer

2020 ◽  
Vol 24 ◽  
pp. 102120 ◽  
Author(s):  
María Victoria Cano-Cortes ◽  
Saúl Abenhamar Navarro-Marchal ◽  
María Paz Ruiz-Blas ◽  
Juan José Diaz-Mochon ◽  
Juan Antonio Marchal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Targeted Treatment

scholarly journals Current status and novel directions in triple negative breast cancer patients. Risk factors. Role of the platinum-based chemotherapy

2016 ◽  
Vol 11 (2) ◽  
pp. 122-126
Author(s):  
Olivia IONESCU ◽  
◽  
Irina BALESCU ◽  
Nicolae BACALBASA ◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Clinical Trials ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Controlled Vocabulary ◽  
Current Status ◽  
Platinum Based Chemotherapy ◽  
Therapeutic Possibilities

Rationale. Breast cancer (BC) has been recognized to be the most common type of cancer in women all over the world. One of the most aggressive subtype of BC is the triple negative breast cancer (TNBC) which is defined by the absence of estrogen receptor (ER) and progesterone receptor (PR) as well as the lack of overexpression of the human epidermal growth factor 2 (HER 2). Aim. As the estrogen and progesterone receptors as well as the expression of HER2 are lacking, a targeted therapy with anti-hormone agents and anti-HER2 cannot be utilized, the therapeutic possibilities for TNBC women are limited. The aim of this review is to present the current scientific data as well as the latest research in TNBC with focus on the risk factors as well as the current role of platinum-based chemotherapeutic agents and their future implications in TNBC treatment. Method. Information about the risk factors associated to TNBC as well as the chemotherapeutic regimens was searched through Pubmed and Medline using controlled vocabulary (e.g. breast cancer) and key words (e.g. neoadjuvant, triple negative, platinum). Systematic reviews, randomized and controlled clinical trials were analyzed. No restrictions regarding date or language were used. Conclusions. TNBC is a complex and heterogeneous disease, divided into many subtypes and with an aggressive evolution. Premenopausal women and African American women are far more likely to develop TNBC. More research is required in order to confirm the association between obesity, BMI, parity, use of oral contraceptives, alcohol and cigarette smoking and TNBC. Randomized clinical trials presented at the San Antonio Symposium suggest that platinum chemotherapy play an important role in the treatment of TNBC, especially early stage TNBC. Tumor-based measures of genomic instability will help to clarify the optimal use and activity of platinum in TNBC. However, it is clear than more epidemiological studies as well as the discovery of novel therapeutic possibilities are mandatory in order to unravel the complexity of this BC subtype, hence offering a chance to women diagnosed with TNBC.

scholarly journals Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles

2017 ◽  
Vol 24 (4) ◽  
pp. R81-R97 ◽  
Author(s):  
Jenny G Parvani ◽  
Mark W Jackson
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Therapeutic Option ◽  
Receptor Expression ◽  
Therapeutic Interventions ◽  
Current Status ◽  
Molecular Features

Over the past decade, RNA interference (RNAi) has been ubiquitously utilized to study biological functionin vitro; however, limitations were associated with its utilityin vivo. More recently, small interfering RNA (siRNA) nanoparticles with improved biocompatibility have gained prevalence as a potential therapeutic option for the treatment of various diseases. The adaptability of siRNA nanoparticles enables the delivery of virtually any siRNA, which is especially advantageous for therapeutic applications in heterogeneous diseases that lack unifying molecular features, such as triple-negative breast cancer (TNBC). TNBC is an aggressive subtype of breast cancer that is stratified by the lack of estrogen receptor/progesterone receptor expression andHER2amplification. There are currently no FDA-approved targeted therapies for the treatment of TNBCs, making cytotoxic chemotherapy the only treatment option available to these patients. In this review, we outline the current status of siRNA nanoparticles in clinical trials for cancer treatment and discuss the promising preclinical approaches that have utilized siRNA nanoparticles for TNBC treatment. Next, we address TNBC subtype-specific therapeutic interventions and highlight where and how siRNA nanoparticles fit into these strategies. Lastly, we point out ongoing challenges in the field of siRNA nanoparticle research that, if addressed, would significantly improve the efficacy of siRNA nanoparticles as a therapeutic option for cancer treatment.

Reverse engineering of triple-negative breast cancer cells for targeted treatment

Maturitas ◽  
2018 ◽  
Vol 108 ◽  
pp. 24-30 ◽  
Author(s):  
Lena Bluemel ◽  
Marie-Kristin von Wahlde ◽  
Joke Tio ◽  
Ludwig Kiesel ◽  
Christof Bernemann
Keyword(s):  
Breast Cancer ◽  
Reverse Engineering ◽  
Cancer Cells ◽  
Triple Negative Breast Cancer ◽  
Breast Cancer Cells ◽  
Triple Negative ◽  
Targeted Treatment

Micellar nanoformulation of lipophilized bortezomib: high drug loading, improved tolerability and targeted treatment of triple negative breast cancer

2017 ◽  
Vol 5 (28) ◽  
pp. 5658-5667 ◽  
Author(s):  
Kaiqi Wu ◽  
Ru Cheng ◽  
Jian Zhang ◽  
Fenghua Meng ◽  
Chao Deng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Drug Loading ◽  
Targeted Treatment ◽  
High Drug ◽  
Micellar Systems ◽  
Efficacious Drug ◽  
High Drug Loading

Lipophilization of bortezomib with pinanediol enables efficacious drug loading and targeted tumor chemotherapy with reduction-sensitive self-crosslinked micellar systems.

scholarly journals Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
David J. Hiller ◽  
Quyen D. Chu
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Expression Patterns ◽  
Progesterone Receptors ◽  
Parp Inhibitors ◽  
Current Status ◽  
Brca Mutations ◽  
Basal Like Breast Cancer ◽  
Her 2

Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer that is clinically defined as lacking estrogen and progesterone receptors, as well as being ERBB2 (HER-2) negative. Without specific therapeutic targets, TNBC carries a worse prognosis than other types of breast cancer in the absence of therapy. Research has now further differentiated breast cancer into subtypes based on genetic expression patterns. One of these subtypes, basal-like, frequently overlaps with the clinical picture of TNBC. Additionally, both TNBC and basal-like breast cancer link to BRCA mutations. Recent pharmaceutical advances have created a class of drugs, poly(ADP-ribose) polymerase (PARP) inhibitors, which are showing potential to effectively treat these patients. The aim of this paper is to summarize the basis behind PARP inhibitors and update the current status of their development in clinical trials for the treatment of TNBC.

Targeted Treatment of Triple-Negative Breast Cancer

2021 ◽  
Vol 27 (1) ◽  
pp. 50-58
Author(s):  
Joanna A. Young ◽  
Antoinette R. Tan
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Targeted Treatment

scholarly journals Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles

2021 ◽  
Vol Volume 16 ◽  
pp. 7497-7515
Author(s):  
Jingbin Huang ◽  
Wenjing Lai ◽  
Qing Wang ◽  
Qin Tang ◽  
Changpeng Hu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Targeted Treatment ◽  
Rbc Membrane
Sign in / Sign up

Export Citation Format

Share Document